LUND, SWEDEN--(Marketwire - September 08, 2009) - Lund, Sweden, September 8, 2009 - Active Biotech AB’s (NASDAQ OMX Nordic: ACTI) collaboration partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announce information regarding the upcoming novel data to be presented at ECTRIMS (25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis) in Düsseldorf, Germany September 9-12, 2009.
To read the complete press release, please see www.tevapharm.com.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 4:15 p.m. CET on September 8, 2009.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
For further information, please contact:
Tomas Leanderson
President & CEO
Tel: +46 46 19 20 95
E-mail: Email Contact
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0) 46 19 11 54
E-mail: Email Contact
